Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.59 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.56 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.56 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.56 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | SELP | P16109 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7415347 | 0.98 | PPARA (0.58) | PPARAPLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL503571 | 0.95 | PLAAT3 (0.61) | PPARAPLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL7156624 | 0.89 | PLAAT3 (0.56) | PPARAPLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL10599216 | 0.89 | PPARA (0.50) | PPARAPLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL9175204 | 0.89 | PPARA (0.58) | PPARAPLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL2221405 | 0.89 | KDM4E (0.59) | PPARAPLAAT3PLAAT5PLAAT2PLAAT4 | |
| SCHEMBL347209 | 0.88 | FFAR4 (0.61) | ALOX5LDHAKDM4EATMCA12 | |
| SCHEMBL7410835 | 0.88 | GAA (0.65) | ALOX5SELP | |
| SCHEMBL7824983 | 0.88 | ALOX5 (0.71) | ALOX5 | |
| SCHEMBL12439701 | 0.88 | HPGD (0.61) | PPARAALOX5SELPPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605618-B2 | Antidiabetic agents; hypoglycemic agents; anticholesterol agents; side effect reduction | WYETH | 2003-08-12 | — | — | US | disclosed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | disclosed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | disclosed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
| US-5446194-A | Pharmacologically active catechol derivatives | ORION-YHTYMA OY (FI) | 1995-08-29 | — | — | US | disclosed |
| US-5283352-A | Transferase inhibitor | ORION-YHTYMA OY (FI) | 1994-02-01 | — | — | US | disclosed |
| US-5112861-A | Inhibitors of catechol-methyl-transferase enzyme, levodopa | ORION-YHTYMA OY (FI) | 1992-05-12 | — | — | US | disclosed |
| US-4963590-A | ENZYME INHIBITOR FOR TREATING PARKINSON'S DISEASE ALONG WITH DOPA;POTENTIATION | ORION-YHTYMA OY (FI) | 1990-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | PPARA 1137/4885PLAAT3 3933/4885PLAAT5 4342/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | PPARA 1205/4885PLAAT3 4004/4885PLAAT5 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.